CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

Share this content:
In this study, patients were randomly assigned to receive nivolumab, ipilimumab, or a combination of both.
In this study, patients were randomly assigned to receive nivolumab, ipilimumab, or a combination of both.

Nivolumab with or without ipilimumab has shown long-lasting survival outcomes as a first-line treatment for patients with advanced melanoma in the phase 3 CheckMate 067 trial, with results published in Lancet Oncology.

In this study, 945 treatment-naïve patients with stage III or IV melanoma and known BRAFV600mutation status were randomly assigned to receive nivolumab alone (316 patients), ipilimumab (315 patients), or the combination (nivolumab plus ipilimumab; 314 patients). Primary end points were overall survival and progression-free survival.

Nivolumab alone or with ipilimumab outperformed ipilimumab alone for both end points. Median overall survival was 36.9 months (95% CI, 28.3-not reached) for the nivolumab group, 19.9 months (95% CI, 16.9-24.6) for the ipilimumab group, and not reached (95% CI, 38.2 months-not reached) for the combination group.

Median progression-free survival for the nivolumab group was 6.9 months (95% CI, 5.1-10.2), 2.9 months (95% CI, 2.8-3.2) for the ipilimumab group, and 11.5 months (95% CI, 8.7-19.3) for the combination group.

Four treatment-related deaths occurred: neutropenia in the nivolumab group (1 patient), colon perforation in the ipilimumab group (1 patient), and one patient each from liver necrosis and cardiomyopathy in the combination treatment.

Grade 3-4 treatment-related adverse events (TRAEs) occurred in 22% of patients in the nivolumab cohort, 28% in the ipilimumab group, and 59% in the combination group. The most common grade 3 TRAEs were diarrhea in both the nivolumab and combination groups, and colitis in the ipilimumab group, and increased lipase was the most common grade 4 TRAE in all groups.

Nivolumab alone or with ipilimumab showed good long-term efficacy against advanced melanoma, the authors concluded.


Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[published online October 22, 2018]. Lancet Oncol. doi: 10.1016/S1470-2045(18)30700-9

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs